Figure 9
From: PGRN protects against colitis progression in mice in an IL-10 and TNFR2 dependent manner
IL-10 signaling is required for PGRN-mediated protection from experimental colitis.
(A) DSS colitis was established in wild-type mice, 5 mice were injected with an IL-10R monoclonal antibody to block IL-10 signaling whereas 5 mice were injected with an isotype antibody, then body weight was measured. (B) Representative intestinal sections from mice treated with isotype antibody or anti-IL10R mAb. (C) Body weight. TNBS colitis was established in IL-10−/− mice and these mice were treated with PBS or PGRN. Eight mice per group were used. (D) Representative histological changes of colon sections from IL-10−/− mice treated with PBS or PGRN. (E) Foxp3, IFN-γ and IL-17 level of T cells from MLN were detected by FACS method. All data represent means ± SE of three independent experiments. *p < 0.05; **p < 0.01. Scale bars, 200 μm.
